Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evolving Trends for Selected Treatments of T1a Renal Cell Carcinoma.
Doolittle J, Piotrowski J, Zuk K, Jacobsohn K, Langenstroer P, See W, Johnson S. Doolittle J, et al. Among authors: johnson s. Urology. 2019 Oct;132:136-142. doi: 10.1016/j.urology.2019.06.029. Epub 2019 Jul 4. Urology. 2019. PMID: 31279691
Factors Influencing Patient Selection of Urologists.
Berger GK, Medairos R, Regala P, Jacobsohn K, Langenstroer P, See WA, Johnson SC. Berger GK, et al. Urology. 2020 Mar;137:19-25. doi: 10.1016/j.urology.2019.08.066. Epub 2019 Dec 4. Urology. 2020. PMID: 31809771
The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020?
Lemke E, Sahasrabudhe D, Guancial E, Bylow K, Johnson S, Messing E, Kilari D. Lemke E, et al. Among authors: johnson s. Clin Genitourin Cancer. 2020 Aug;18(4):e478-e483. doi: 10.1016/j.clgc.2020.01.003. Epub 2020 Jan 27. Clin Genitourin Cancer. 2020. PMID: 32085986 Review.
AUTHOR REPLY.
Berger GK, Medairos R, Johnson SC. Berger GK, et al. Urology. 2020 Mar;137:24-25. doi: 10.1016/j.urology.2019.08.069. Urology. 2020. PMID: 32115069 No abstract available.
Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial.
Hall WA, Bedi M, Kilari D, Bylow KA, Burfeind J, Johnstone C, Siker M, Currey A, See WA, Nelson A, Johnson S, Straza M, Lawton CAF. Hall WA, et al. Among authors: johnson s. Pract Radiat Oncol. 2021 Nov-Dec;11(6):527-533. doi: 10.1016/j.prro.2021.03.006. Epub 2021 Apr 10. Pract Radiat Oncol. 2021. PMID: 33848618 Free PMC article. Clinical Trial.
12,423 results
You have reached the last available page of results. Please see the User Guide for more information.